NAFLD/NASH

The current nomenclature of NAFLD supports a diagnosis "in negative", based on the exclusion of other causes of liver disease. An international consensus panel has recently suggested a new nomenclature, metabolic dysfunction-associated fatty liver disease (MAFLD),1 based on the identification of the associated metabolic risk factors to support active case finding. The burden of the disease is large, with an estimated prevalence of 25.2% in the general population,2 increasing to more than 50% in high-risk groups such as diabetic and obese patients.